

III. Alternative TTC values - ELSIE approach

第 0 好 9 第 0 好 8 9

www.sitox.org

BOLOGNA 20-22 Febbraio 2023

Pericolo, rischio e rapporto rischio-beneficio



PDA Journal of Pharmaceutical Science and Technology



Development of Duration-Based Non-Mutagenic Thresholds of Toxicological Concern (TTC) Relevant to Parenteral Extractables and Leachables (E&Ls)

Melisa J. Masuda-Herrera, Joel P. Bercu, Thomas H. Broschard, et al.

PDA Journal of Pharmaceutical Science and Technology 2022, Access the most recent version at doi:10.5731/pdaipst.2021.012693

- ELSIE Consortium was established in 2007;
- It comprised together leading scientists and industries of biotechnology, pharmaceutical and medical devices to share safety information on extractables and leachables;
- "We do not compete on safety".

Gather Data for compounds in **ELSIE Database** Remove mutagens or **Assessment for Mutagenicity** predicted mutagens Remove compounds Non-Mutagenic E&L compounds with inadequate n=459 (all routes of exposure) toxicity data PODs for Non-Mutagenic E&L LOAEL to NOAEL **Calculation Adjust** Compounds (all routes of n=252 for Bioavailability exposure) TTC for E&L Compounds **Duration Adjustment** n=252 (Duration Adjusted) **Factors Adjusted Parenteral** PODs for E&L n=252 95th Percentile/100 Compounds

Development of Duration-Based Non-Mutagenic Thresholds of Toxicological Concern (TTC) Relevant to Parenteral Extractables and Leachables (E&Ls).

PDA Journal of Pharmaceutical Science and Technology January 2022







Organic Parenteral TTCs for Non-Mutagenic Impurities

	≤1 year	≤10 years	>10 years to lifetime
Parenteral TTC [µg/day]	180	110	35

Development of Duration-Based Non-Mutagenic Thresholds of Toxicological Concern (TTC) Relevant to Parenteral Extractables and Leachables (E&Ls). PDA Journal of Pharmaceutical Science and Technology January 2022






























Congresso Nazionale Società Italiana di Tossicologia www.sitox.org BOLOGNA 20-22 Febbraio 2023 Pericolo, rischio e rapporto rischio-beneficio



ELSIE workflow





































Eurofins Approach





TTC for Non-Mutagenic Impurities Cramer Classes

- Class I contains substances of simple chemical structure with known metabolic pathways and innocuous end products which suggest a low order of oral toxicity.
- Class II contains substances that are intermediate. They
 possess structures that are less innocuous than those in
 Class I but they do not contain structural features that are
 suggestive of toxicity like those in Class III.
- Class III contains substances with a chemical structures that permit no strong initial impression of safety and may even suggest a significant toxicity.

Type of TTC value	TTC value in μg/kg bw/day	TTC value in μg/day (50kg person)
Cramer Class III	1.5	75
Cramer Class II	9	450
Cramer Class I	30	1500

TTC for Non-Mutagenic Impurities Escher Classes

• Cramer Classes were developed considering oral exposure data. The RepDose database of Fraunhofer ITEM, Germany gives information on 650 substances, including 203 substances for which administration was by the inhalation route (Escher et al., 2010). The latter were reduced to 136 substances after exclusion of those with structural alerts for genotoxicity, and from these they derived systemic TTC values of 180 μg/person per day for substances in Cramer Class I and 4 μg/person per day for substances in Cramer Class III.


Type of TTC value	TTC value in μg/person/day	TTC value in µg/day (50kg person)
Cramer Class III and Cramer Class II	4	3
Cramer Class I	71	59












- ELSIE si basa su un E&L database
 - ELSIE è specifico per la via di somministrazione parenterale
 - Toxicity assessment specifico
 - Sensibilizzazione e PQRI?
 - Predizioni in silico?

An hybrid approach





Pericolo, rischio e rapporto rischio-beneficio

...quindi si conclude l'Era di Cramer?






































www.sitox.org

BOLOGNA 20-22 Febbraio 2023

Pericolo, rischio e rapporto rischio-beneficio



GRAZIE PER L'ATTENZIONE

ConsultingItaly@eurofins.com



























